SI Stock Forecast & Price Target

Shoulder Innovations is attractive because its commercial momentum is being driven by strong surgeon adoption, with Q2 revenue of about $17.2M up 56.0% Y/Y and unit volumes rising 48.9% Y/Y, while management also raised FY26 revenue guidance to $67M-$69M. The company’s differentiated shoulder-specific portfolio, led by the InSet system and supported by durable gross margins, gives it a compelling clinical and economic position in a US market of roughly $1.7B that is growing in the high-single digits. A growing pipeline of new products, including fracture, metal sensitivity, revision, and a robot planned for submission in 1H27, expands the addressable market by $200M+ and should support higher ASPs, deeper surgeon penetration, and operating leverage over time.

Shoulder Innovations is viewed negatively because its Q2 beat was modest and did not change the core issue that the company remains small, loss-making, and dependent on continued share gains to justify its growth story. Although revenue rose 56% to $17.2M with gross margin at 78.3%, the adjusted EBITDA loss was still about $8M, and the outlook is constrained by a highly competitive market, slower surgeon adoption, ASP degradation, and the need for additional capital to reach profitability. Even with a top-line CAGR of about 27% and a 5.0x EV/Sales multiple, the company’s limited operating history, existing debt, and exposure to slower shoulder market growth make execution risk high.